

Changes to preferred drug designations under the medical benefit for most members, starting Jan. 1

For dates of service on or after Jan. 1, 2026, Blue Cross Blue Shield of Michigan and Blue Care Network are making changes to preferred drug designations for some products.

These changes will affect:

- Blue Cross Blue Shield of Michigan and Blue Care Network commercial —
 - All fully insured members (group and individual), except MESSA members
 - Members who have coverage through self-funded groups that participate in the Oncology Value Management program. Refer to the document titled [Oncology Value Management program participation list for self-funded groups](#).

Note: This requirement doesn't apply to Blue Cross commercial members who have coverage through the Blue Cross and Blue Shield Federal Employee Program[®] or through the Blue Cross commercial UAW Retiree Medical Benefits Trust plans.

- Medicare Plus Blue and BCN Advantage members

Changes to preferred drug designations

We're changing preferred drug designations as shown in the following table.

| Product | Lines of business | Preferred drugs | |
|---------------|---|--|---|
| | | Before Jan. 1, 2026 | On or after Jan. 1, 2026 |
| Pegfilgrastim | <ul style="list-style-type: none"> Blue Cross commercial BCN commercial | <ul style="list-style-type: none"> Fulphila[®] Nyvepria[®] Udenyca[®], Udneyca Onbody[™] | <ul style="list-style-type: none"> Fulphila Neulasta, Neulasta OnPro Udenyca, Udenyca Onbody |
| | <ul style="list-style-type: none"> Medicare Plus Blue BCN Advantage | <ul style="list-style-type: none"> Fulphila[®] Neulasta[®], Neulasta OnPro[®] Nyvepria[®] | <ul style="list-style-type: none"> Fulphila Neulasta, Neulasta OnPro |
| Trastuzumab | <ul style="list-style-type: none"> Blue Cross commercial BCN commercial | <ul style="list-style-type: none"> Kanjinti[®] Ogivri[®] | <ul style="list-style-type: none"> Ogivri Ontruzant[®] Trazimera[®] |
| | <ul style="list-style-type: none"> Medicare Plus Blue BCN Advantage | <ul style="list-style-type: none"> Trazimera[®] | <ul style="list-style-type: none"> Ontruzant[®] Trazimera[®] |

| Product | Lines of business | Preferred drugs | |
|-----------|--|--|--|
| | | Before Jan. 1, 2026 | On or after Jan. 1, 2026 |
| Rituximab | <ul style="list-style-type: none"> Blue Cross commercial BCN commercial Medicare Plus Blue BCN Advantage | <ul style="list-style-type: none"> Riabni® Ruxience® | <ul style="list-style-type: none"> Riabni Ruxience Truxima® <p>Note: Rituximab preferred drugs won't require prior authorization.</p> |

How existing prior authorizations are affected by these changes

- For commercial members with Kanjinti and Nyvepria authorizations, members can continue with therapy until their authorization expires. Upon renewal, providers will be directed to use a preferred product.
- For Medicare Advantage members with Nyvepria authorizations, we encourage providers to transition members to a preferred drug for dates of service on or after Jan. 1, 2025.

How to submit prior authorization requests

Submit prior authorization requests to OncoHealth using one of the following methods:

- Through the OncoHealth OneUMTM portal, which you can access by logging in to our provider portal (availity.com*), clicking *Payer Spaces* and then clicking the BCBSM and BCN logo. This takes you to the Blue Cross and BCN payer space where you'll click the *OncoHealth Provider Portal* tile.
- By calling OncoHealth at 1-888-916-2616

More about prior authorization requirements

Prior authorization isn't a guarantee of payment. As always, health care practitioners need to verify eligibility and benefits for members.

For additional information on requirements related to drugs covered under the medical benefit, refer to the following drug lists:

- Blue Cross commercial and BCN commercial members: [Medical oncology prior authorization list for Blue Cross commercial fully insured and BCN commercial members](#)
- Medicare Plus Blue and BCN Advantage members: [Medical Drug and Step Therapy Prior Authorization List for Medicare Plus Blue and BCN Advantage members](#)

We'll update the pertinent drug lists to reflect the information in this message prior to the effective date.



**Blue Cross
Blue Shield
Blue Care Network**
of Michigan

Nonprofit corporations and independent licensees
of the Blue Cross and Blue Shield Association

Provider alert

**Blue Cross commercial, Medicare Plus BlueSM,
BCN commercial and BCN AdvantageSM**

Categories: Authorizations/referrals, Pharmacy

Date posted: Oct. 2, 2025

[Subscribe](#) to Provider Alerts Weekly, a weekly email with a list of links to the previous week's provider alerts.

Availity® is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal and electronic data interchange services.

OncoHealth is an independent company supporting Blue Cross Blue Shield of Michigan and Blue Care Network by providing cancer support services.